Investing.com - Needham lowered its price target on Amphastar Pharmaceuticals (NASDAQ:AMPH) to $30 from $34 while maintaining a Buy rating following the company’s fourth-quarter results. Despite the ...

Researchers conducted an observational study using real‑world data to compare the effectiveness and safety of initiating three fixed‑dose long‑acting muscarinic antagonist (LAMA)-long‑acting beta‑2 ...

Amphastar Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $0.73 EPS, expectations were $0.97. Operator: Greetings, and welcome to the Amphastar Pharmaceuticals Fourth Quarter ...

On February 26, 2026, H.C. Wainwright raised the price target on United Therapeutics Corporation (NASDAQ:UTHR) from $525 to $600 while maintaining a Buy rating. The company has announced that it is ...

United Therapeutics Corporation (NASDAQ:UTHR) is one of the top 10 stocks Warren Buffett would buy in 2026. On February 26, 2026, H.C. Wainwright raised the price target on United Therapeutics ...

Amphastar Pharmaceuticals remains a 'Hold' as growth and margin headwinds persist amid its transition from generics to a proprietary pipeline. AMPH’s legacy generics are declining, branded products ...

Amphastar is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and ...

Liquidia has rapidly captured 16% market share in pulmonary hypertension since launching Yutrepia in June 2025, with momentum likely to continue. LQDA's superior product profile is driving patient ...

Liquidia Corp. (LQDA) on Thursday released its financial results for the fourth quarter (Q4), highlighting strong early traction in the commercial rollout of its respiratory drug, YUTREPIA. The ...

The White House called reports that President Trump will address the nation on Saturday following the U.S. strikes on Iran “inaccurate.” “This reporting was inaccurate, the White House has not given ...